We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Tamiflu Confirmed Effective for Avian Flu

By HospiMedica staff writers
Posted on 01 Aug 2005
A new study in mice has confirmed that Tamiflu (oseltamivir), used against influenza strains, is effective against the avian flu virus H5N1.

The study was conducted by researchers at St. More...
Jude Children's Hospital (Memphis, TN, USA) who used oseltamivir to treat mice infected with the H5N1 virus. The highest dose used was equivalent to the dose currently recommended for humans sick with the flu. Of 80 mice infected with the virus, 20 received a placebo, 30 were given oseltamivir at one of three dosage levels for five days, and 30 received the drug at one of three dosage levels for eight days. None of the mice receiving placebo survived. Only five of the 10 mice given the highest daily dose for five days survived. Although oseltamivir suppressed the virus in the mice, the virus continued to grow if the drug was stopped after five days.

Mice given the drug for eight days, on the other hand, fared better. Survivors included one of 10 mice given the lowest daily dose, 2 of 10 given the middle-range daily dose, and eight of 10 given the highest daily dose. Oseltamivir decreases the ability of the influenza virus to spread from infected cells to uninfected cells by inhibiting neuraminidase, a protein required for the virus to exit infected cells.

Public health experts fear that this avian flu strain could develop the ability to easily spread from person to person and kill millions in a pandemic. "The H5N1 avian flu viruses are in a process of rapid evolution,” noted Elena A. Goborkova, Ph.D., of St. Jude Children's Hospital. "Our results provide baseline information that will be needed for further studies on preventing and treating avian flu with antiviral drugs.

The St. Jude researchers say further study is needed to see if using higher doses of oseltamivir for a longer period of time can prevent the H5N1 virus in the lungs from gaining a foothold and then spreading to the brain.




Related Links:
St. Jude Children's Hospital

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Ultrasound System
FUTUS LE
Xenon Light Source
CLV-S400
Portable Jaundice Management Device
Nymphaea
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.